Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Nucleic acid analogue wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Genetically modified crops wikipedia , lookup
Genetically modified organism containment and escape wikipedia , lookup
Designer baby wikipedia , lookup
Genetically modified food wikipedia , lookup
Griffith University Institutional Biosafety Committee Exempt Dealing Evaluation Report (To be completed and submitted on-line) IBC Reference No: 1. This reference number will be advised upon receipt of application Project Supervisor: Staff working on project: School: Research Centre: Group (Health or SEET): Campus: Select one campus Internal Postal Address: Business Hours Contact Number: Email Address: Click here to link to the IBC website 2. Project Title: Commencement Date: 3. Completion Date: Facilities used: (i) Campus: Select one campus Building: Are these facilities certified? (ii) Campus: Select one campus Containment Level: Building: Are these facilities certified? (iii) Campus: Select one campus Campus: Select one campus Building: Campus: Select one campus Building: Campus: Select one campus Are these facilities certified? 4. Room: Containment Level: Building: Are these facilities certified? (vi) Room: Containment Level: Are these facilities certified? (v) Room: Containment Level: Are these facilities certified? (iv) Room: Room: Containment Level: Building: Room: Containment Level: Is this a storage application for your Exempt Dealing GMO? D:\81918591.doc Page 1 of 4 (if yes, go to Section 9 – Exemption Category) 5. Project summary: Briefly describe the project, including the aims of the proposed dealing, method of producing GMO’s and their use. (This should be written in plain English) ALL REFERENCES TO HOST CELLS, VECTORS, GENES OF INTEREST, TRANSFECTION SYSTEMS, ETC SHOULD INCLUDE SOME EXPLANATION OF THEM. PLEASE WRITE THE NAMES OF THE GENES AND/OR PROTEINS IN FULL THE FIRST TIME RATHER THAN JUST PROVIDING ACRONYMS. (This field will automatically increase in size as you type – there is no limitation to size of field) 6. Please provide details of disposal methods for GMO’s (This field will automatically increase in size as you type – there is no limitation to size of field) 7. Are the GMO’s being transported between facilities or off campus? 8. If yes, please specify transport details 9. Exemption Category 2 3 4 A dealing with a genetically modified Caenorhabditis elegans, unless: (a) An advantage is conferred on the animal by the genetic modification; or (b) As a result of the genetic modification, the animal is capable of secreting or producing an infectious agent. Any dealing with an animal into which genetically modified somatic cells have been introduced, if: (a) The somatic cells are not capable of giving rise to infectious agents as a result of the genetic modification; and (b) The animal is not infected with a virus that is capable of recombining with the genetically modified nucleic acid in the somatic cells. (1) Any dealing involving a host/vector system mentioned in Part 2 of this Schedule and producing no more than 10 litres of GMO culture in each vessel containing the resultant culture. (2) The donor nucleic acid: (a) Must satisfy either of the following requirements: (i) It must not be derived from organisms implicated in, or with a history of causing, disease in human beings, animals, plants or fungi; or (ii) It must be characterised and not known to alter the host range or mode of transmission, or increase the virulence, pathogenicity or transmissibility of the host or vector; and (b) Must not code for a toxin with an LD50 of less than 100g/kg; and (c) Must not code for a toxin with an LD50 of 100g/kg or more, if the intention is to express the toxin at high levels; and (d) Must not be uncharacterised nucleic acid from a toxin-producing organism; and (e) Must not include a viral sequence unless the donor nucleic acid: (i) (ii) (f) 5 Is missing at least 1 gene essential for viral multiplication that: Is not available into the cell into which the nucleic acid is introduced, and Will not become available during the dealing; and Is incapable of correcting a defect in the host/vector system leading to production of replication competent virions; and Must not confer an oncogenic modification. Any dealing involving shot-gun cloning, or the preparation of a cDNA library, in a host/vector system D:\81918591.doc Page 2 of 4 mentioned in item 1 of part 2 of this schedule, if the donor nucleic acid is not derived from either: 10. (a) A pathogen; or (b) A toxin-producing organism. GMO Class of GMO Details Algae Animal Bacteria Fungi Plant Protozoa Virus 11. Modified trait(s) and gene(s) responsible Class of modified trait Details Virus resistance Fungal resistance Bacterial resistance Disease resistance Pest resistance Herbicide tolerance Antibiotic resistance Pesticide resistance Abiotic stress resistance Altered agronomic characteristics Altered horticultural characteristics Altered nutritional characteristics Altered physical product characteristics Altered physiological characteristics Altered pharmaceutical characteristics Attenuation Antigen expression Protein expression Growth factor expression Altered biosensor characteristics Altered bioremediation characteristics Altered biocontrol characteristics D:\81918591.doc Page 3 of 4 Reporter/marker gene expression Immuno-modulatory protein expression Other 12. Statement of compliance I certify that the GMO dealings associated with this project will comply with conditions and requirements as required by the OGTR and GU-IBC at all times. (electronic signature or e-mail title accepted) Signature of Project Supervisor: Date: Please email the completed Exempt Dealing Evaluation Report to the Griffith University Institutional Biosafety Committee: [email protected] 13. IBC Declaration The IBC has evaluated this dealing and agrees that it is an exempt dealing as specified as specified by Schedule 2 of the Gene Technology Regulations 2001. Name of IBC: Griffith University – IBC Name of IBC Chair: Dr. Ian Peak Signature of IBC Chair: Date: Version No: V01.2 APPROVED DOCUMENT ON INTRANET ONLY – UNCONTROLLED DOCUMENT WHEN PRINTED. Description Document Custodian Approving Authority Date Review Date Exempt Dealing Project Application Lynette Wilde Griffith University IBC D:\81918591.doc Page 4 of 4 08 September 2010 01 July 2012